PVLA vs WVE
PVLA: A clinical-stage biopharmaceutical company developing proprietary therapeutics for rare skin diseases and vascular malformations following the merger of Pieris Pharmaceuticals and Legacy Palvella. WVE: A clinical-stage biotechnology company developing a versatile, multimodal RNA medicine platform to treat rare and common diseases without the need for complex delivery vehicles like lipid nanoparticles.
Side-by-side fundamentals
| Metric | PVLA | WVE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $142.18 | $5.74 | |
| Market cap as of 2026-07-23 | $2.0B | $1.1B | |
| PEG as of 2026-07-23 | n/a | -0.11 | |
| Net margin as of 2026-07-23 | -39.7% | -255.7% | PVLA higher |
| Operating margin as of 2026-07-23 | -47.8% | -274.2% | PVLA higher |
| ROE as of 2026-07-23 | -56.9% | -55.7% | WVE higher |
| ROA as of 2026-07-23 | -42.5% | -42.8% | PVLA higher |
| Debt / equity as of 2026-07-23 | 0.09 | 0.00 | WVE lower |
| Revenue growth (YoY) as of 2026-07-23 | -97.2% | -31.6% | WVE higher |
| Revenue CAGR (3y) SEC XBRL | +13.4% | +127.1% | WVE higher |
| Beta as of 2026-07-23 | -0.20 | -1.33 | |
| 1-year return as of 2026-07-22 close | +294.9% | -27.6% | PVLA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.